IBIO, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
IBIO, INC. (IBIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 1.00% for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2025-09-05
- IBIO, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 1.00%, a 0.00% change from fiscal 2024.
- IBIO, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 1.00%.
- IBIO, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2014 was 0.00%, a 100.00% decline from fiscal 2013.
- IBIO, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2013 was 3.00%, a 88.46% decline from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-06-30 | 1.00% 10-K · filed 2025-09-05 |
| 2024-06-30 | 1.00% 10-K/A · filed 2024-09-24 |
| 2014-06-30 | 0.00% 10-K · filed 2014-09-29 |
| 2013-06-30 | 3.00% 10-K · filed 2014-09-29 |
| 2012-06-30 | 26.00% 10-K/A · filed 2013-10-04 |
| 2011-06-30 | -7.00% 10-K/A · filed 2012-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |